Compare iShares Self-Driving EV and Tech (IDRV) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Natera Inc. Common Stock — how do they compare? iShares Self-Driving EV and Tech trades at $31.81 (market cap $259.03M), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 220.2× iShares Self-Driving EV and Tech's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 75 Days and Natera Inc. Common Stock for 0 Days on average.
| IDRV | NTRA | |
|---|---|---|
Market Cap | $259.03M | $57.03B |
Volume | 21,908 | 1,131,157 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $425.64 |
52-Week Low | $32.18 | $179.42 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $32.78, up 0.43% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from lukewarm US electric vehicle adoption despite global EV sales growth. Key support sits at $32 with resistance at $33-34 levels, while oscillators remain neutral suggesting potential consolidation.
The EV sector faces mixed signals with regulatory uncertainty and oil price volatility creating near-term challenges. Long-term prospects remain tied to global EV adoption trends, particularly in China and Europe where growth continues. Investors should weigh regulatory risks against the sector's structural growth trajectory.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
